secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001558370-24-004927
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics clears IND for APR-1051; updates on ATRN-119 Phase 1 at AACR
-------------------------------------------------------------------------------

- IND for next-gen WEE1 inhibitor APR-1051 cleared; first patient dosing expected June 2024 in Phase 1 ACESOT-1051 trial.
- ATRN-119 (ATR inhibitor) Phase 1/2a: enrolling 550 mg cohort; no DLTs, no Grade 4+ AEs; stable disease in two patients (one on treatment 188+ days).
- Preclinical data show APR-1051 has >50-fold reduced PLK off-target inhibition vs ZN-c3; well tolerated with minimal hematotoxicity in mice.
- New preclinical ATRN-333 combination with lomustine for glioblastoma shows synergy; intracranial delivery via convection-enhanced device.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024004927/0001558370-24-004927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837024004927/apre-20240410x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer